
Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability
RIGL is a profitable, three-drug company, reporting a net income of $17.5M for 2024. RIGL's three marketed drugs, Tavalisse (fostamatinib) remains the major generator of net product sales, accounting for two-thirds of Q4'24's net product sales. …